SMS Pharmaceuticals Ltd. is a global player in API manufacturing, boasting a strong research and manufacturing team supported by state-of-the-art facilities. What began as a single-facility, single-product manufacturing company in 1990 has grown into a multi-location group with a product list spreading across an array of therapeutic segments. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyderabad, India.
Shri Ramesh Babu Potluri, Chairman and Managing Director – a visionary in the pharma industry, started SMS Pharmaceuticals Ltd in the year 1990, taking over a sick facility and successfully turning it around by changing products within a short period. The company has transformed from a single-unit entity to a diversified pharmaceutical corporation with a global footprint.
SMS Pharma has demonstrated consistent financial performance. As of recent market data, the company has a market capitalization of ₹2,327.56 crore (as of 20th May 2025), with total revenue of ₹783 crore and a profit of ₹68.4 crore.
The company's latest quarterly results indicate a healthy growth trajectory:
Q4 FY25 Results:
- Revenue jumped 0.88% since the last year's same period to ₹249.62 crore in Q4 FY25.
- Net profit jumped 17.59% since the last year's same period to ₹20.32 crore in Q4 FY25.
Q3 FY25 Results:
- Consolidated net profit surged 58.9% to ₹18.24 crore in Q3 FY25, as against ₹11.48 crore recorded in Q3 FY24.
- Revenue from operations rose 7.4% to ₹173.35 crore in the quarter ended 31 December 2024.
Q2 FY25 Results:
- Net profit rose 20.20% to ₹14.10 crore in the quarter ended September 2024, as against ₹11.73 crore during the previous quarter ended September 2023.
- Sales rose 18.07% to ₹196.75 crore in the quarter ended September 2024, as against ₹166.64 crore during the previous quarter ended September 2023.
- Market Capitalization: ₹2,327.56 crore (as of 20 May 2025)
- Total Revenue: ₹783 crore
- Total Profit: ₹68.4 crore
- Q4 FY25 Net Profit: ₹20.32 crore
- Q3 FY25 Net Profit: ₹18.24 crore
- Q2 FY25 Net Profit: ₹14.10 crore
- Promoter Holding: 66.3% (as of Mar 2025, increased from 64.67% in Jun 2024)
- Return on Equity (3 years): 7.39%
- PE Ratio: 34.80 (as of 20 May 2025)
- PB Ratio: 3.74 (as of 20 May 2025)
SMS Pharmaceuticals Ltd (SMS Pharma) specializes in manufacturing active pharmaceutical ingredients (API) and intermediates. It is an integrated pharmaceutical company with a diverse product portfolio under various therapeutic categories including Anti-ulcer, anti-fungal, anti-migraine, anti-viral, anti-diabetic, and anti-retroviral. The company holds a global leadership position in 10+ therapeutic products.
Key products include Ibuprofen, Tenofavir, Ranolazine, Levetiracetam, Lamuvidine, Lamotrigine, Efavirenz, Sitagliptin, Famotidine, Rizatriptan Benzoate, Tadalafil, Sumatriptan Succinate, Itraconazole, and Eletriptan HBr. The company offers 45+ products to over 800 customers across 75+ countries.
SMS Pharmaceuticals operates state-of-the-art manufacturing facilities in Visakhapatnam and Hyderabad, producing high-quality pharmaceutical products for global markets. These two facilities have capacities of 120 KL and 3,000 KL, respectively. With four multi-product facilities in operation and two research centers, SMS has graduated into the big league, employing more than 1000 individuals.
The company's facilities are designed to comply with international quality standards, including USFDA, WHO cGMP, and European Suitability Norms, ensuring world-class manufacturing capabilities that meet stringent global regulatory requirements.
SMS Pharma has a strong global presence, exporting its products to approximately 75 countries. The company was granted export house status in 1997-98. From a single unit and single product entity, SMS has grown into a group with multiple facilities and multiple products, serving a customer base in more than 70 countries.
The company has established itself as a trusted partner in the global pharmaceutical supply chain, delivering high-quality APIs to international markets while maintaining strong regulatory compliance across different jurisdictions.
SMS Pharma provides comprehensive analytical services, specializing in method development, validation, and transfer. The company offers expertise in a wide range of testing, including assays, organic impurities, enantiomeric purity, dissolution, content uniformity, and residual solvents. Additionally, SMS Pharmaceuticals is actively involved in contract research activities related to peptides.
SMS Pharmaceuticals Ltd (SMSPHARMA) has shown significant stock appreciation, with its share price moving up by 100.23% on BSE over the last 3 years. The 52-week high for SMS Pharmaceuticals Ltd (SMSPHARMA) is ₹398, and the 52-week low is ₹175.25.
SMS Pharmaceuticals represents a well-established pharmaceutical company with a strong foundation in API manufacturing, global reach, and consistent financial performance. The company's diversified product portfolio, world-class manufacturing facilities, and growing international presence position it as a significant player in the global pharmaceutical ingredients market.
